A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.

Twelve patients were treated with didox, a new ribonucleotide reductase inhibitor, by 36 h infusion. The maximum tolerated dose was 6 g m-2, above which dose-limiting hepatic toxicity was observed. Patient tolerance was significantly better using the 36 h infusion compared to patients receiving the...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmichael, J., Cantwell, B. M., Mannix, K. A., Veale, D., Elford, H. L., Blackie, R., Kerr, D. J., Kaye, S. B., Harris, A. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971305/
https://www.ncbi.nlm.nih.gov/pubmed/2183873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971305/
https://www.ncbi.nlm.nih.gov/pubmed/2183873

Ejemplares similares